aibioAmgen AMGN class action and settlement news
Top story · Sep 2, 2026 · aibio.space
TScan cuts 75% of staff and pauses phase 3 trial for lack of capital
TScan will cut about 75% of its workforce, stop enrolling its phase 3 ALLOHA-2 trial for lack of capital and focus on solid tumors. Amgen is also ending a Crohn's disease collaboration, and Nasdaq has warned that the stock failed the $1.00 minimum bid for 30 straight trading days.
- Ticker
- AMGN
- Listing
- NASDAQ, United States
- Next date
- H2 2026
- Chief executive
- Robert A. Bradway
Desk view · Opinion · Updated Oct 22, 2026
Amgen's newer brands carry the load while MariTide chases a crowded field
Amgen's newer brands are growing fast enough to offset biosimilar losses, and it raised 2026 guidance in August. Its long-term growth case rests on MariTide in a crowded obesity market, while Tavneos and a July data breach are open risks.
Read the full desk viewaibio.space Investor Rank · Opinion
7/10 Positive view
Newer brands are growing fast enough to cover biosimilar losses and guidance rose, while heavy debt and the crowded MariTide obesity bet remain open questions.
- Technology
- 2/2
- Odds
- 1/2
- Balance sheet
- 1/2
- Risk
- 1/2
- Momentum
- 2/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Broad and commercial. Newer brands such as Repatha, Evenity and Tezspire grew 37% to 42% in Q2 2026.
- Odds
- Mid-range for the obesity bet. MariTide is in phase 3, where about 57.8% of drugs reach a filing in industry data.
- Balance sheet
- Cash-rich but leveraged. $14.0 billion of cash against $57.3 billion of debt at June 30, with $3.5 billion of Q2 free cash flow.
- Main risk
- Biosimilar erosion. Prolia and Xgeva fell about a third in Q2 and Amgen expects declines to speed up.
- Watch next
- Second-half phase 3 completions. Dazodalibep and Tezspire in eosinophilic esophagitis are due by year end.
Top news on Amgen
- Distress
TScan cuts 75% of staff and pauses phase 3 trial for lack of capital
TScan will cut about 75% of its workforce, stop enrolling its phase 3 ALLOHA-2 trial for lack of capital and focus on solid tumors. Amgen is also ending a Crohn's disease collaboration, and Nasdaq has warned that the stock failed the $1.00 minimum bid for 30 straight trading days.
- Legal
Amgen agrees to settle Roofers securities class action over IRS tax disclosures
Amgen, CEO Robert Bradway and CFO Peter Griffith agreed to settle the New York class action, subject to court approval. Derivative suits against directors are stayed.
- Legal
Amgen's ChemoCentryx securities class action settlement gets preliminary approval
Homyk v. ChemoCentryx named ChemoCentryx and its CEO over TAVNEOS statements. A California federal court preliminarily approved a class settlement on June 12, 2026; final hearing is October 29.
Questions investors ask
What is aibio.space's Investor Rank for Amgen?
7 out of 10, our positive view. Newer brands are growing fast enough to cover biosimilar losses and guidance rose, while heavy debt and the crowded MariTide obesity bet remain open questions. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
What is Amgen's 2026 revenue guidance?
Amgen expects 2026 total revenues of $38.2 billion to $39.4 billion and non-GAAP EPS of $22.30 to $23.50. It raised the range on August 4, 2026. Source
Why does the FDA want to withdraw Amgen's Tavneos?
The FDA's drug center proposed on April 27, 2026 to withdraw approval, alleging a lack of substantial evidence of effectiveness and untrue statements in the original application, after reports of serious liver injury. Amgen requested a hearing, and the drug stays on the market during the process. Source
What happened in the Amgen data breach?
Amgen disclosed in July 2026 that attackers took data, including proprietary data and patient protected health information, from cloud environments run by third-party providers. It said products, manufacturing and financial reporting were not affected. Source
Who is Amgen's new CFO?
Thomas Dittrich, former CFO of Galderma and Shire, became Amgen's chief financial officer on September 1, 2026. He replaced Peter Griffith, who is retiring. Source
What stage is Amgen's obesity drug MariTide in?
MariTide is in phase 3 in the MARITIME program, covering weight management, cardiovascular outcomes, heart failure and sleep apnea. Three more phase 3 studies in type 2 diabetes are set to start in 2026. Source
What is the latest Amgen (AMGN) stock news?
Our latest story on Amgen, dated Aug 5, 2026: "Amgen agrees to settle Roofers securities class action over IRS tax disclosures". Amgen, CEO Robert Bradway and CFO Peter Griffith agreed to settle the New York class action, subject to court approval. Derivative suits against directors are stayed. Source
Is Amgen facing a lawsuit?
Our latest legal story, dated Aug 5, 2026: "Amgen agrees to settle Roofers securities class action over IRS tax disclosures". Amgen, CEO Robert Bradway and CFO Peter Griffith agreed to settle the New York class action, subject to court approval. Derivative suits against directors are stayed. Claims in lawsuits are allegations until a court rules. Source
What is Amgen's market cap?
We do not publish live share prices. In its annual report, Amgen Inc. put the market value of shares held by non-affiliates (public float) at $150.10 billion as of Jun 30, 2025. Source
Is Amgen a smaller reporting company?
SEC records list Amgen Inc.'s filer category as: Large accelerated filer. Source
Where is Amgen headquartered?
SEC records list its business address as ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320. Source
When does Amgen's fiscal year end?
Amgen Inc.'s fiscal year ends on December 31, per SEC records. Source
What did Amgen last file with the SEC?
Its most recent filing in our record is a 10-Q filed 2026-08-05. All of its filings are on SEC EDGAR. Source
What industry is Amgen in?
Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source
Which other companies' news mentions Amgen?
Amgen is named in 1 of our story about other companies, most recently: "TScan cuts 75% of staff and pauses phase 3 trial for lack of capital" (Sep 2, 2026). Source
Legal and investor matters
- Other
Amgen discloses material cybersecurity incident involving exfiltrated data
In a Form 8-K under Item 1.05, Amgen said it identified unauthorized activity in July 2026 involving data stored in cloud environments hosted by third-party providers, and learned that some data, including patient protected health information, was exfiltrated. Amgen determined on 2026-07-29 that the incident is material. It said it was not reasonably likely to have a material impact on its financial condition or results of operations, and the investigation was ongoing.
- Class action
Amgen reaches agreement to settle IRS-disclosure securities class action
Roofers Local No. 149 Pension Fund sued Amgen, Robert Bradway and Peter Griffith on 2023-03-13 in the Southern District of New York on behalf of an alleged class of shareholders who owned stock between 2020-07-29 and 2022-04-27, alleging misleading statements and omissions about the potential tax liability claimed by the IRS. The 10-Q filed 2026-08-05 says the parties reached an agreement to settle, subject to court approval, and that plaintiffs moved for preliminary class settlement approval on 2026-07-20. The filing does not state the settlement amount.
- Litigation
Court rules on Regeneron motion against Amgen defenses and counterclaims in PAVBLU patent case
In Regeneron's June 2025 suit over Amgen's aflibercept biosimilar PAVBLU, the Northern District of West Virginia on 2026-07-07 granted in part and denied in part Regeneron's motion to strike certain Amgen defenses and dismiss certain counterclaims. It dismissed with prejudice Amgen's inequitable conduct, patent misuse and unclean hands defenses and its counterclaims for unenforceability, Sherman Act monopolization and attempted monopolization, and California unfair competition tied to the '099 patent. It dismissed without prejudice similar counterclaims tied to patents asserted in the 2024 action, and denied the motion as to Amgen's prosecution laches defense and counterclaim.
- Class action
Court preliminarily approves ChemoCentryx securities class action settlement
ChemoCentryx, acquired by Amgen, and its then CEO were named in 2021 securities class actions in the Northern District of California over statements about the Tavneos application. The court granted summary judgment to defendants on 2025-08-15, the lead plaintiff appealed, and the parties agreed to settle on 2026-01-27. The 10-Q says the court preliminarily approved the settlement on 2026-06-12 and set final approval for 2026-10-29. The filing does not state the amount.
- Litigation
Enbrel antitrust class action against Amgen stayed pending Fourth Circuit appeal
CareFirst filed a proposed antitrust class action against Amgen on 2024-08-06 in the Eastern District of Virginia, alleging a 2004 agreement with Roche unlawfully extended Enbrel patent life and delayed biosimilars. The court partly granted Amgen's motion to dismiss on 2025-09-30. Amgen filed its opening Fourth Circuit brief on 2026-06-08, and on 2026-06-10 the district court stayed the case pending the appeal, according to the 10-Q filed 2026-08-05.
- Regulatory
Amgen awaits Tax Court decision in IRS dispute and gets new draft IRS adjustments
Amgen is contesting IRS adjustments for 2010 to 2015 in the U.S. Tax Court, where trial ended 2025-01-17. The court ordered supplemental closing briefs, filed 2026-05-20, and Amgen expects a decision no earlier than late 2026 or early 2027. In April 2026 Amgen received a draft notice of proposed adjustment for 2016 to 2018. The 10-Q says the adjustments, if sustained in full, could have a material impact on its financial statements.
- Financing
Amgen sells $4.0 billion of senior notes in four series
On 2026-02-17 Amgen issued and sold four series of senior notes: $1,000,000,000 of 4.200% notes due 2031, $1,750,000,000 of 4.850% notes due 2036, $500,000,000 of 5.500% notes due 2046 and $750,000,000 of 5.650% notes due 2056. Net proceeds were approximately $3,961,495,000 after underwriters' discounts and estimated expenses. The notes were registered under an effective Form S-3 filed 2026-02-13.
- Other
Amgen and Kyowa Kirin agree to terminate license and collaboration agreement
On 2026-01-30 Amgen and Kyowa Kirin signed a termination agreement ending their License and Collaboration Agreement dated 2021-06-01. The 8-K says the termination becomes effective upon receipt of regulatory approval. The filing does not describe the products involved or any payments, and portions of the exhibit were omitted as not material.
- Litigation
Health plans and Sandoz file antitrust suits over Amgen Enbrel patent position
Sandoz sued Amgen on 2025-04-11 in the Eastern District of Virginia on antitrust and tortious interference claims tied to Enbrel patent rights. In July and August 2025, seven lawsuits by health insurers were filed in California Superior Court in Ventura County with allegations similar to the CareFirst class action. Several were later dismissed voluntarily or joined into the Centene case, and Amgen filed demurrers in 2026.
- Litigation
Jury finds for Regeneron against Amgen in Repatha bundling antitrust case
On 2025-05-15 a jury in the District of Delaware found for Regeneron on its federal and state antitrust and tortious interference claims over Amgen's contracting practices for Repatha, Enbrel and Otezla. The 10-K says damages under either alternative claim total $406.8 million, and Regeneron must elect one. Amgen says the verdict is inconsistent with the law and evidence, and has recorded no liability. Post-trial motions were heard 2025-08-27.
- Derivative suit
Delaware Chancery consolidates derivative suits over Amgen IRS disclosures
David Hamilton, Charles Blackburn and Robert Bryla filed derivative actions in the Delaware Court of Chancery on 2024-10-16, 2024-11-07 and 2024-12-06 against Amgen's CEO, CFO and directors, with Amgen as nominal defendant, alleging breach of fiduciary duty. The facts alleged are the same as in the Roofers securities class action. The court consolidated the cases on 2025-04-09 and the 10-K says the case is stayed pending final judgment in Roofers.
- Derivative suit
Federal derivative suits over Amgen IRS disclosures are stayed
Federal derivative suits tied to the Roofers securities class action include DM Cohen (filed 2025-02-12 in the Southern District of New York, consolidated with earlier Martin and Clearwater cases on 2025-04-21) and Sieveking and Tierney (filed 2025-04-02 in the Delaware federal district court). They allege Exchange Act and fiduciary duty claims. Both are stayed pending final judgment in the Roofers class action, according to the 10-K filed 2026-02-13.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| MariTide (maridebart cafraglutide) | Obesity, type 2 diabetes, cardiovascular outcomes, heart failure, sleep apnea | Phase 3 (MARITIME program) Source |
| Repatha (evolocumab) | High cholesterol, cardiovascular risk reduction | Marketed; VESALIUS-CV analyses ongoing Source |
| Imdelltra (tarlatamab) | Extensive-stage small cell lung cancer | Marketed; EU approval May 2026 Source |
| Dazodalibep | Sjogren's disease | Phase 3; two studies to complete H2 2026 Source |
| Tezspire (tezepelumab) | Eosinophilic esophagitis, COPD | Phase 3; EoE study to complete H2 2026 Source |
| Tavneos (avacopan) | Approved 2021; acquired with ChemoCentryx | Marketed; FDA proposed withdrawal April 2026, hearing requested Source |
Opinion · Devil's advocate
Fact-check-o-meter
Amgen's Q2 release does not mention the FDA's formal Tavneos withdrawal proposal, the July cyber incident or the IRS notice that its filings describe
Amgen's revenue figures match across its release and 10-Q. The gaps are in what the release leaves out. It refers to CDER's request to "voluntarily withdraw" Tavneos, which the 10-Q also records from January 2026, but not the formal FDA proposal of April 27, 2026 to withdraw approval. It also does not mention the July cyber incident, which Amgen's 8-K calls material while stating it is not reasonably likely to have a material impact on financial condition or results, or the IRS notice and Tax Court dispute described in the 10-Q.
Press release vs filing · weight high
Tavneos: 'request to voluntarily withdraw' versus a formal withdrawal proposal
The company said: "The Company continues to engage the FDA regarding the Center for Drug Evaluation and Research's request to voluntarily withdraw TAVNEOS from the U.S. market." source
The record says: The 10-Q says that on January 16, 2026 the FDA requested that Amgen voluntarily withdraw TAVNEOS, that Amgen informed the FDA on January 28, 2026 that it did not intend to withdraw it, and that "On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS." It also says Tavneos remains on the market during the process. It adds that "The proposal alleges that there is new information indicating lack of substantial evidence of effectiveness for the drug and that ChemoCentryx's application that resulted in FDA approval contained untrue statements of material facts." It also states that the FDA's March 2026 communication alerted patients to "serious liver injury cases, including fatal cases", and that the Tavneos intangible assets carry "a carrying value of $ 2.4 billion". source
Our view: These are the FDA's allegations, which Amgen disputes, and the release does say a hearing was requested on June 1. But the release does not mention the April proposal, its allegations, the liver safety communication or the $2.4 billion asset, and the 10-Q warns that future cash flow changes "could unfavorably impact" its recoverability.
Press release vs filing · weight medium
Material cyber incident absent from the results release
The record says: The 8-K under Item 1.05 says: "The Company has since learned that some of its data, including proprietary data, patient protected health information, and other information, has been exfiltrated from these cloud environments." It also says the Company determined on July 29, 2026 that the incident is material, and believes it is "not reasonably likely to have a material impact on the Company's financial condition or results of operations". The 10-Q's risk factors refer back to this 8-K. source
Our view: Amgen filed the 8-K promptly, so the matter is disclosed. The Q2 release, issued days later, does not mention it, so an investor reading only the release would not see an incident the company itself classed as material. The investigation was described as ongoing.
Science · weight medium
Tavneos trial was double blind; the FDA proposal questions the evidence
The company said: "We continue to engage with the U.S. Food and Drug Administration (FDA) and believe that TAVNEOS demonstrates clinical effectiveness and a favorable benefit-risk profile." source
The record says: ClinicalTrials.gov lists the phase 3 ADVOCATE trial (NCT02994927) as randomized with quadruple masking and 331 actual participants, with remission at week 26 and sustained remission at week 52 as primary outcomes. The 10-Q says Amgen submitted "data from an independent, blinded re-adjudication of certain study data that supported the FDA's approval of TAVNEOS" on July 23, 2026. source
Our view: The registry shows a well-masked design, so the issue the 10-Q describes is how the study data were analysed and adjudicated, not a missing control arm. The outcome of the re-adjudication is not yet disclosed, and the FDA may enter summary judgment if no hearing is granted.
Press release vs filing · weight medium
IRS notice and Tax Court dispute are not in the release
The record says: The 10-Q says the IRS reissued its notice of proposed adjustments in "May and July 2026" and that "If sustained in full, the adjustments set forth in the NOPA could have a material impact on our financial statements. We intend to contest the NOPA." source
Our view: The release gives full-year tax guidance but does not mention the IRS matters. The 10-Q states no amount for the NOPA, but describes the separate Tax Court case as seeking additional federal tax of about $3.6 billion for 2010 to 2012 and about $5.1 billion plus about $2.0 billion of penalties for 2013 to 2015, with a decision expected no earlier than late 2026 or early 2027.
Legal and disclosure record · weight medium
Patent and biosimilar suits disclosed; FDA proceeding on Tavneos
The record says: Note 13 of the 10-Q covers "certain recent developments" and lists Prolia/XGEVA BPCIA litigation against Amneal, Dr. Reddy's and Alkem, and "Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (action filed January 10, 2024)" and a second Regeneron action filed June 17, 2025 over PAVBLU, a CareFirst of Maryland antitrust class action now before the Fourth Circuit, and the U.S. Tax Court case Amgen Inc. & Subsidiaries v. Commissioner of Internal Revenue. The FDA withdrawal proposal for Tavneos is a regulatory proceeding described in the intangible assets note. source
Our view: These are matters Amgen discloses itself. Note 13 points to the 2025 10-K for the full list, which we did not review, so we make no statement about securities litigation beyond what the 10-Q note discusses.
Stock chart
SEC filings and registration
- SEC name
- Amgen Inc
- CIK
- 318154
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- AMGN (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
- Phone
- (805)447-1000
- Shares outstanding
- 540,632,005 as of 2026-07-30 (10-Q filed 2026-08-05)
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction